法国I-STEM招聘哈钦森吉尔福德早衰综合征研究博士后

Created in 2004, I-Stem is a non-profit organization resulting from the combination of two different and independent entities: a joined Research Unit of INSERM (UMR-861 unit), the University Evry-Val d’Essonne and the laboratory managed by CECS (Centre pour l’Etude des Cellules Souches). Financially supported by the French Muscular Disease Association (AFM), I-Stem integrates three different activities: a basic biological research, a technological research for development and application, and a biological resource center. The main objective of I-Stem is to explore the therapeutic potential of pluripotent stem cells in order to propose to patients therapeutic products applied to monogenic diseases. I-stem is an uncontested worldwide leader in the field of pluripotent stem cells conducing drug screenings for rare diseases and cell therapy clinical trials.
Our teaml is working on Hutchinson Gilford progeria syndrome (HGPS), a rare genetic disorder causing a systemic accelerating aging in children. To date, because of the absence of cellular model compatible with high throughput screening, all the treatments evaluated on patients were drugs identified through hypothesis driven strategies and repositioning indications. Thanks to the pluripotency and self-renewal properties of induced pluripotent stem cells, we succeed to develop and perform two screenings of thousands of small molecules on this disease on two different readouts and identified potential drugs for this syndrome. This project will aim to evaluate the therapeutic effect of the new compounds by monitoring their effect in several other HGPS related phenotypes and understand their molecular mechanisms.